Peptide comparison
Both stimulate growth hormone release, but through different pathways: CJC-1295 mimics GHRH and ipamorelin acts like ghrelin. That difference is exactly the reason they are combined.
Compare mechanism, class, receptors and evidence. All compounds are offered with ≥99% purity verified by HPLC and a batch COA.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analog | GHRP / ghrelin mimetic |
| Receptor | GHRH receptor | GHS-R secretagogue receptor |
| Action | Pushes the positive GH stimulus | Activates GHS-R and attenuates somatostatin |
| Selectividad | About the GHRH axis | Highly selective: minimal effect on cortisol and prolactin |
| Duration | Medium (without DAC) or prolonged (with DAC) | Corta |
CJC-1295 is a GHRH analog that acts on the GHRH receptor, "pushing" the growth hormone stimulus. Ipamorelin is a GHRP that acts on the GHS-R receptor (the ghrelin receptor) and also attenuates the somatostatin brake; it stands out for its high selectivity ("clean" profile, with minimal effect on cortisol and prolactin).
Because they work through complementary pathways, combining them produces a GH pulse greater than the sum of each one separately. It is the canonical example of rational GHRH + GHRP synergy.
💡 Want the complete scientific foundations? See the Peptide guide or the Certification in Peptide Science.
CJC-1295 is a GHRH analog (it acts on the GHRH receptor); ipamorelin is a GHRP that acts on the GHS-R receptor (the ghrelin receptor). They stimulate GH through different pathways.
Because their pathways are complementary: CJC-1295 pushes the GH stimulus and ipamorelin, besides activating GHS-R, attenuates somatostatin. Together they generate a GH pulse greater than each one separately.
Its high selectivity: it stimulates GH release with minimal effect on cortisol and prolactin, unlike other GHRPs such as GHRP-2 or GHRP-6.
Purity ≥99% verificada por HPLC and batch COA.
View full catalog →